Life sciences partner Greg Levine (Washington, D.C.) is quoted in an Institutional Investor (subscription required) article examining how biopharmaceutical companies are being forced to justify product value in the face of price gouging allegations in the specialty drug market. In the article, Greg discusses how drug makers are trying to communicate the value that new medicines deliver with educational messages, and the challenges of staging a rational debate in the current polarized environment.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.